Market Intelligence chevron_right Medical Care chevron_right Gastroenteropancreatic Neuroendocrine Tumor Therapeutics
Global Report 2021

Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size, Status and Forecast 2024-2031

calendar_todayPublished: Dec 2021 descriptionPages: 98 categoryCategory: Medical Care
cloud_downloadRequest Sample Report
mailPre-Order Enquiry
local_offerGet Discount 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Chemotherapy
        1.2.3 Peptide-Receptor Radionuclide Therapy
        1.2.4 Others
    1.3 Market by Application
        1.3.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Ambulatory Surgical Centers
        1.3.5 Others
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Perspective (2016-2027)
    2.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Growth Trends by Regions
        2.2.1 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Share by Regions (2016-2021)
        2.2.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Regions (2022-2027)
    2.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Industry Dynamic
        2.3.1 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Trends
        2.3.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Drivers
        2.3.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Challenges
        2.3.4 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Revenue
        3.1.1 Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Revenue (2016-2021)
        3.1.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Players (2016-2021)
    3.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue
    3.4 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Concentration Ratio
        3.4.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue in 2020
    3.5 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Key Players Head office and Area Served
    3.6 Key Players Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Solution and Service
    3.7 Date of Enter into Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Breakdown Data by Type
    4.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Type (2016-2021)
    4.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Type (2022-2027)

5 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Breakdown Data by Application
    5.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Application (2016-2021)
    5.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2016-2027)
    6.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type
        6.2.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021)
        6.2.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027)
        6.2.3 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2027)
    6.3 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application
        6.3.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021)
        6.3.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027)
        6.3.3 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2027)
    6.4 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country
        6.4.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2016-2021)
        6.4.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2016-2027)
    7.2 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type
        7.2.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021)
        7.2.2 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027)
        7.2.3 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2027)
    7.3 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application
        7.3.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021)
        7.3.2 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027)
        7.3.3 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2027)
    7.4 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country
        7.4.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2016-2021)
        7.4.2 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2016-2027)
    8.2 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type
        8.2.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2027)
    8.3 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application
        8.3.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2027)
    8.4 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region
        8.4.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2016-2027)
    9.2 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type
        9.2.1 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021)
        9.2.2 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027)
        9.2.3 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2027)
    9.3 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application
        9.3.1 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021)
        9.3.2 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027)
        9.3.3 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2027)
    9.4 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country
        9.4.1 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2016-2021)
        9.4.2 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2016-2027)
    10.2 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type
        10.2.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2027)
    10.3 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application
        10.3.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2027)
    10.4 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country
        10.4.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Novartis
        11.1.1 Novartis Company Details
        11.1.2 Novartis Business Overview
        11.1.3 Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
        11.1.4 Novartis Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
        11.1.5 Novartis Recent Development
    11.2 Pfizer
        11.2.1 Pfizer Company Details
        11.2.2 Pfizer Business Overview
        11.2.3 Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
        11.2.4 Pfizer Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
        11.2.5 Pfizer Recent Development
    11.3 Fresenius Kabi
        11.3.1 Fresenius Kabi Company Details
        11.3.2 Fresenius Kabi Business Overview
        11.3.3 Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
        11.3.4 Fresenius Kabi Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
        11.3.5 Fresenius Kabi Recent Development
    11.4 Teva Pharmaceuticals
        11.4.1 Teva Pharmaceuticals Company Details
        11.4.2 Teva Pharmaceuticals Business Overview
        11.4.3 Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
        11.4.4 Teva Pharmaceuticals Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
        11.4.5 Teva Pharmaceuticals Recent Development
    11.5 Sun Pharma
        11.5.1 Sun Pharma Company Details
        11.5.2 Sun Pharma Business Overview
        11.5.3 Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
        11.5.4 Sun Pharma Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
        11.5.5 Sun Pharma Recent Development
    11.6 Hutchison China MediTech Limited
        11.6.1 Hutchison China MediTech Limited Company Details
        11.6.2 Hutchison China MediTech Limited Business Overview
        11.6.3 Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
        11.6.4 Hutchison China MediTech Limited Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
        11.6.5 Hutchison China MediTech Limited Recent Development
    11.7 Exelixis, Inc.
        11.7.1 Exelixis, Inc. Company Details
        11.7.2 Exelixis, Inc. Business Overview
        11.7.3 Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
        11.7.4 Exelixis, Inc. Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
        11.7.5 Exelixis, Inc. Recent Development
    11.8 Tarveda Therapeutics
        11.8.1 Tarveda Therapeutics Company Details
        11.8.2 Tarveda Therapeutics Business Overview
        11.8.3 Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
        11.8.4 Tarveda Therapeutics Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
        11.8.5 Tarveda Therapeutics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Chemotherapy
    Table 3. Key Players of Peptide-Receptor Radionuclide Therapy
    Table 4. Key Players of Others
    Table 5. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
    Table 8. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Regions (2016-2021)
    Table 9. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 10. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Regions (2022-2027)
    Table 11. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Trends
    Table 12. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Drivers
    Table 13. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Challenges
    Table 14. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Restraints
    Table 15. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Players (2016-2021) & (US$ Million)
    Table 16. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Players (2016-2021)
    Table 17. Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics as of 2020)
    Table 18. Ranking of Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Companies by Revenue (US$ Million) in 2020
    Table 19. Global 5 Largest Players Market Share by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (CR5 and HHI) & (2016-2021)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Solution and Service
    Table 22. Date of Enter into Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 25. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type (2016-2021)
    Table 26. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 27. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 28. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
    Table 29. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Application (2016-2021)
    Table 30. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 31. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 32. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 33. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 34. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 35. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 36. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 37. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 38. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 39. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 40. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 41. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 42. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 43. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 44. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 45. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 46. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 47. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 48. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2016-2021) & (US$ Million) 
    Table 49. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2022-2027) & (US$ Million) 
    Table 50. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 51. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 52. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 53. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 54. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 55. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 56. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 57. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 58. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 59. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 60. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 61. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 62. Novartis Company Details
    Table 63. Novartis Business Overview
    Table 64. Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
    Table 65. Novartis Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021) & (US$ Million)
    Table 66. Novartis Recent Development
    Table 67. Pfizer Company Details
    Table 68. Pfizer Business Overview
    Table 69. Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
    Table 70. Pfizer Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021) & (US$ Million)
    Table 71. Pfizer Recent Development
    Table 72. Fresenius Kabi Company Details
    Table 73. Fresenius Kabi Business Overview
    Table 74. Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
    Table 75. Fresenius Kabi Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021) & (US$ Million)
    Table 76. Fresenius Kabi Recent Development
    Table 77. Teva Pharmaceuticals Company Details
    Table 78. Teva Pharmaceuticals Business Overview
    Table 79. Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
    Table 80. Teva Pharmaceuticals Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021) & (US$ Million)
    Table 81. Teva Pharmaceuticals Recent Development
    Table 82. Sun Pharma Company Details
    Table 83. Sun Pharma Business Overview
    Table 84. Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
    Table 85. Sun Pharma Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021) & (US$ Million)
    Table 86. Sun Pharma Recent Development
    Table 87. Hutchison China MediTech Limited Company Details
    Table 88. Hutchison China MediTech Limited Business Overview
    Table 89. Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
    Table 90. Hutchison China MediTech Limited Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021) & (US$ Million)
    Table 91. Hutchison China MediTech Limited Recent Development
    Table 92. Exelixis, Inc. Company Details
    Table 93. Exelixis, Inc. Business Overview
    Table 94. Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
    Table 95. Exelixis, Inc. Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021) & (US$ Million)
    Table 96. Exelixis, Inc. Recent Development
    Table 97. Tarveda Therapeutics Company Details
    Table 98. Tarveda Therapeutics Business Overview
    Table 99. Tarveda Therapeutics Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021) & (US$ Million)
    Table 100. Tarveda Therapeutics Recent Development
    Table 101. Research Programs/Design for This Report
    Table 102. Key Data Information from Secondary Sources
    Table 103. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type: 2020 VS 2027
    Figure 2. Chemotherapy Features
    Figure 3. Peptide-Receptor Radionuclide Therapy Features
    Figure 4. Others Features
    Figure 5. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application: 2020 VS 2027
    Figure 6. Hospitals Case Studies
    Figure 7. Clinics Case Studies
    Figure 8. Ambulatory Surgical Centers Case Studies
    Figure 9. Others Case Studies
    Figure 10. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Report Years Considered
    Figure 11. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 12. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 13. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Regions: 2020 VS 2027
    Figure 14. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Regions (2022-2027)
    Figure 15. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Players in 2020
    Figure 16. Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics as of 2020
    Figure 17. The Top 10 and 5 Players Market Share by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue in 2020
    Figure 18. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type (2016-2021)
    Figure 19. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type (2022-2027)
    Figure 20. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 21. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type (2016-2027)
    Figure 22. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application (2016-2027)
    Figure 23. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2016-2027)
    Figure 24. United States Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Canada Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 27. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type (2016-2027)
    Figure 28. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application (2016-2027)
    Figure 29. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2016-2027)
    Figure 30. Germany Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. France Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. U.K. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Italy Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Russia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Nordic Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type (2016-2027)
    Figure 38. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application (2016-2027)
    Figure 39. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region (2016-2027)
    Figure 40. China Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Japan Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. South Korea Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. India Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Australia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type (2016-2027)
    Figure 48. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application (2016-2027)
    Figure 49. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2016-2027)
    Figure 50. Mexico Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Brazil Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type (2016-2027)
    Figure 54. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application (2016-2027)
    Figure 55. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2016-2027)
    Figure 56. Turkey Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. Saudi Arabia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. UAE Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. Novartis Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
    Figure 60. Pfizer Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
    Figure 61. Fresenius Kabi Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
    Figure 62. Teva Pharmaceuticals Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
    Figure 63. Sun Pharma Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
    Figure 64. Hutchison China MediTech Limited Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
    Figure 65. Exelixis, Inc. Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
    Figure 66. Tarveda Therapeutics Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
    Figure 67. Bottom-up and Top-down Approaches for This Report
    Figure 68. Data Triangulation
    Figure 69. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Novartis
Pfizer
Fresenius Kabi
Teva Pharmaceuticals
Sun Pharma
Hutchison China MediTech Limited
Exelixis, Inc.
Tarveda Therapeutics

Frequently Asked Questions

What is the USP of the report? expand_more
Gastroenteropancreatic Neuroendocrine Tumor Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
What are the key content of the report? expand_more
Gastroenteropancreatic Neuroendocrine Tumor Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
What are the value propositions and opportunities offered in this market research report? expand_more
Gastroenteropancreatic Neuroendocrine Tumor Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.